Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
The F.D.A.’s own internal inquiry said there was “no evidence” its interactions with Biogen were “anything but appropriate,” given the data’s complexity and the importance of Alzheimer’s, but it issued four recommendations to prevent future problems. The congressional report said that more than a year later, the F.D.A. still had not fully implemented them. The…
Details